33 results about "Her2 receptor" patented technology

Methods for treating a subject with a cancer that is characterized by overexpression of HER2 receptor protein using a combination of interleukin-2 (IL-2) or variant thereof and at least one anti-HER2 antibody or fragment thereof are provided. These anti-tumor agents are administered as two separate pharmaceutical compositions, one containing IL-2 (or variant thereof), the other containing at least one anti-HER2 antibody (or fragment thereof), according to a dosing regimen. Administering of these two agents together potentiates the effectiveness of the anti-HER2 antibody alone, resulting in a positive therapeutic response that is improved with respect to that observed with this anti-tumor agent.

The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.

The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor.The invention provides antibodies or fragments thereof that recognises an epitope of a HER2 receptor truncated form, said epitope being defined by a sequence included in SEQ ID NO: 2.The invention also provides a method of cancer diagnosis, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.

The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor.The invention provides antibodies or fragments thereof that recognise an epitope of the HER2 receptor truncated form CTF-611, said epitope being defined by a sequence included in SEQ ID NO: 2, and that are capable of discriminating between CTF-611 and CTF-616 (represented by SEQ ID NO:7), preferably additionally capable of discriminating between CTF-611 and CTF-613 (represented by SEQ ID NO:6).The invention also provides a method of cancer diagnosis using the disclosed antibodies, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.

The present invention relates to novel therapeutic antibodies directed against HER2 (ErbB2), as well as recombinant polyclonal anti-HER2 antibody compositions, and use of the antibodies and antibody composition for treatment of cancers. The antibody composition comprises at least three recombinant antibodies that bind distinct epitopes of HER2. Two of the antibodies bind to HER2 on the surface of a cell such that they generate a cross-linked antibody-receptor lattice on the cell surface and thereby result in HER2 receptor internalization. The third antibody in the composition binds HER2 such that it blocks heterodimerization between HER2 and HER3.

The related chalketoxime shown as the formula (1) is prepared by heating and reflux reacting the 2', 4'-dihydroxy -6'-methoxyl-3', 5'-dimethylchalcone and hydroxylamine hydrochloride in pyridine, which has well solvability, fit to direct inject for drug, restrains obviously all of the activity of blood vessel endothelium growth factor receptor, HER2 receptor and Tyr kinase as PDGFR receptor, the external growth of cells for breast cancer and liver cancer, and the phosphorylation of KDR in ECV304 cell, HER2 in MDA-MB-453 cell and PDGFR receptor in C6 cell, and benefit to treat tumor.

The present invention relates to a method of diagnosis and therapy of cancers expressing the HER2 receptor.The invention provides antibodies or fragments thereof that recognise an epitope of the HER2 receptor truncated form CTF-611, said epitope being defined by a sequence included in SEQ ID NO: 2, and that are capable of discriminating between CTF-611 and CTF-616 (represented by SEQ ID NO:7), preferably additionally capable of discriminating between CTF-611 and CTF-613 (represented by SEQ ID NO:6).The invention also provides a method of cancer diagnosis using the disclosed antibodies, which comprises the detection of the presence of the HER2 receptor truncated form consisting of the amino acid sequence SEQ ID NO: 1 in a patient sample.

The invention provides a polypeptide compound with a HER2 targeting function. The polypeptide compound with the HER2 targeting function is formed by connecting a HER2 affinity with a bifunctional chelating agent through a polypeptide sequence; the polypeptide sequence is Met-Val-Lys; the general structural formula of the polypeptide compound is shown in formula (I) as shown in specification, wherein R is a HER2 affinity molecule and X is a bifunctional chelator group. The invention also provides a radiolabelled complex targeting HER2 by taking the polypeptide compound as a ligand. The radiolabeled complex provided by the invention can be used as a radioactive diagnostic probe for evaluating the HER2 receptor of breast cancer, and the probe can reduce the concentration of the kidney under the condition of keeping the uptake of the tumor unchanged, so that the target-to-non-target ratio of the tumor is improved, and the radiation dose to the kidney is reduced. The invention also provides a preparation method of the polypeptide compound and the radiolabelled complex, and application of the polypeptide compound and the radiolabelled complex in preparation of a HER2 positive breast cancer radioactive diagnosis and treatment probe for humans or animals.

The present invention discloses a fusion protein for treating a breast cancer, wherein the fusion protein is Her2 single-chain fragment antibody-polypeptide, the Her2 single-chain fragment antibody is capable of targeting a Her2 receptor locating on a surface of a breast cancer cell, and the polypeptide is capable of carrying siRNA. The polypeptide includes a protamine polypeptide. The siRNA includes PLK1-siRNA, which is capable of restraining an expression of a knubble malignant phenotype gene. The fusion protein for treating the breast cancer is capable of carrying the PLK1-siRNA, and targeting and importing a Her2 positive breast cancer cell specifically, so as to bring the medicament into the cell. The treatment of the breast cancer is capable of generating a strong effect for restraining the breast cancer growth and transfer, may break a gene suppression effect of the existing antisense oligonucleotide and ribozyme, and becames a novel anti-Her2 gene medicament for treating the breast cancer.

The present invention provides a single chain fragment antibody-polypeptide fusion protein and applications thereof, the protein is a fusion protein which can be combined with Her2 receptors and can carry anti-cancer siRNA drug, and the fusion protein can serve as the vector of the anti-cancer siRNA drug. The single chain fragment antibody is Her2-ScFv, and the polypeptide is nucleoprotamine fragment polypeptide. The sequence of the single chain fragment antibody-polypeptide fusion protein is shown as SEQ ID NO.1. The Her2 single chain fragment antibody and the nucleoprotamine polypeptide fusion protein, which are constructed by the present invention, can be combined with Her2 receptors and can carry the anti-cancer siRNA drug. The fusion protein of the present invention can directionally introduce the anti-cancer siRNA drug into target cancer cells, and a non-viral vector tool is developed to speed up the application of the RNAi technology in clinic.

The present invention relates to anti-HER2 binding molecules (e.g., antibodies and antigen binding fragments thereof), derived HER2-binding molecules (e.g., bispecific anti-HER2 antibodies), and antibody-drug conjugates (ADC) that bind the extracellular domain of the HER2 receptor. Also provided are pharmaceutical formulation comprising the disclosed compositions and method for the treating diseases associated with HER2-mediated signal transduction.

Methods for treating a subject with a cancer that is characterized by overexpression of HER2 receptor protein using a combination of interleukin-2 (IL-2) or variant thereof and at least one anti-HER2 antibody or fragment thereof are provided. These anti-tumor agents are administered as two separate pharmaceutical compositions, one containing IL-2 (or variant thereof), the other containing at least one anti-HER2 antibody (or fragment thereof), according to a dosing regimen. Administering of these two agents together potentiates the effectiveness of the anti-HER2 antibody alone, resulting in a positive therapeutic response that is improved with respect to that observed with this anti-tumor agent.

The invention discloses an application of Chenopodolin in preparation of medicines for treating an ovarian cancer, and belongs to the field of medicines. An in vitro test proves that the Chenopodolin is capable of inhibiting proliferation activity of an ovarian cancer SKOV3 cell; an MTT result shows that distribution of a cell cycle is affected by the Chenopodolin; tumor cells are retarded at a G0 / G1 stage; meanwhile, the Chenopodolin can be combined with a tyrosine kinase phosphorylation ATP binding site of an EGFR / HER2 acceptor to inhibit phosphorylation of tyrosine kinase, so that cell apoptosis is induced by down-regulating expression of HER2 and P-HER2 protein; and the Chenopodolin can be further researched and developed into the medicines for treating the ovarian cancer.

The invention relates to the combined use of anti-EGFR antibodies and anti-Her2 antibodies for the treatment of cancer, especially suitable for cancer expressing high levels of the EGFR type and low levels of HER2. The invention refers in particular monoclonal antibody “trastuzumab” (HERCEPTIN®) directed against the HER2 receptors the efficacy of which can be significantly increased in vivo when combined with monoclonal antibody “matuzumab” (hmAB 425, EMD 72000) directed against EGF receptors. The combination treatment is suitable for patients suffering from cancer having said receptor profile, preferably pancreatic cancer.

The invention discloses chimeric antigen receptor and induced apoptosis enzyme co-fused compound protein, a coding sequence thereof and modified T lymphocyte containing the compound protein. The invention also relates to application of the above compound protein and the modified T lymphocyte in prevention and treatment of breast cancer. The constructed specific chimeric antigen receptor and induced apoptosis enzyme co-fused compound protein has functions of binding to a Her2 receptor, enhancing activated state of T lymphocyte and regulating cell apoptosis. The modified T lymphocyte can efficiently kill Her-2 positive breast cancer cells and can induce modified T lymphocyte apoptosis under the action of the drug AP1903 to terminate the expanding killing effect as a safety guarantee.

A bispecific tetravalent antibody comprising an IgG having a pair of heavy chains and a pair of light chains, and two scFv components being connected to either C or N terminals of the heavy or light chains. The bispecific tetravalent antibody may have a binding specificity for two different epitopes on HER2 receptor.

The invention relates to an application of an EGFR / HER2 receptor tyrosine kinase inhibitor in preparation of a medicine for treating HER2 mutation cancer, and particularly relates to application of acompound shown in the formula A or medicinal salt thereof to preparation of medicine for treating HER2 mutant cancer.

The invention relates to the use of an EGFR / HER2 receptor tyrosine kinase inhibitor in the preparation of medicines for treating cancer. Specifically, the present invention relates to the use of a compound represented by the EGFR / HER2 receptor tyrosine kinase inhibitor formula (I) in the preparation of a drug for treating anti-HER2 drug-resistant cancer.

The invention belongs to the field of radiopharmaceuticals and nuclear medicine, and particularly relates to an 18F marked affinity compound and a preparation method and application thereof. On the one hand, the uptake value of tumors on the 18F marked affinity compound is high, and tumor development sensitivity is high; on the other hand, the uptake value of the liver on the 18F marked affinity compound is low, and toxic and side effects on the liver are small. Animal experiments indicate that the uptake value of tumors on the 18F marked affinity compound is high, the residence time is short, the target / target-to-nontarget ratio is high, good pharmacokinetics characteristics are achieved, the biological properties are good, and the compound can be directly used as a tumor PET photographic developer targeted to an HER2 receptor. The preparation method of the 18F marked affinity compound is low in cost, easy and fast to operate, high in labeling rate and high in radiochemical purity of labeled products, and the prepared 18F marked affinity compound can be clinically applied and popularized as the tumor PET photographic developer targeted to the HER2 receptor.

The invention relates to application of EGFR / HER2 (epidermal growth factor receptor / type-2 human epidermal growth factor receptor) receptor tyrosine kinase inhibitors to preparing medicines for treating cancer, and particularly relates to application of compounds of EGFR / HER2 receptor tyrosine kinase inhibitors to preparing anti-HER2 medicines for treating medicine-resistant cancer. The compoundsof the EGFR / HER2 receptor tyrosine kinase inhibitors are shown as a formula (I).

The present invention relates to the branch of Biotechnology and Medicine, particularly to a method for the selection and treatment of patients with carcinomas of epithelial origin that co-express the HER1 and HER2 receptors without increased expression of these receptors or with the presence of RAS activating mutations. In particular, this method is based on the application of bivalent vaccine compositions which have as active principle the extracellular domains of the HER1 and HER2 receptors or portions thereof and as an adjuvant the very small proteoliposomes derived from the outer membrane proteins of Neisseria meningitidis and the GM3 ganglioside. This method is useful for the treatment of patients whose expression levels of HER1 and HER2 do not allow the monoclonal antibodies against HER1 and / or HER2 to have a therapeutic effect.

The invention discloses chimeric antigen receptor and induced apoptosis enzyme co-fused compound protein, a coding sequence thereof and modified T lymphocyte containing the compound protein. The invention also relates to application of the above compound protein and the modified T lymphocyte in prevention and treatment of breast cancer. The constructed specific chimeric antigen receptor and induced apoptosis enzyme co-fused compound protein has functions of binding to a Her2 receptor, enhancing activated state of T lymphocyte and regulating cell apoptosis. The modified T lymphocyte can efficiently kill Her-2 positive breast cancer cells and can induce modified T lymphocyte apoptosis under the action of the drug AP1903 to terminate the expanding killing effect as a safety guarantee.

The invention belongs to the field of radiopharmaceuticals and nuclear medicine, and particularly relates to an 18F marked affinity compound and a preparation method and application thereof. On the one hand, the uptake value of tumors on the 18F marked affinity compound is high, and tumor development sensitivity is high; on the other hand, the uptake value of the liver on the 18F marked affinity compound is low, and toxic and side effects on the liver are small. Animal experiments indicate that the uptake value of tumors on the 18F marked affinity compound is high, the residence time is short, the target / target-to-nontarget ratio is high, good pharmacokinetics characteristics are achieved, the biological properties are good, and the compound can be directly used as a tumor PET photographic developer targeted to an HER2 receptor. The preparation method of the 18F marked affinity compound is low in cost, easy and fast to operate, high in labeling rate and high in radiochemical purity of labeled products, and the prepared 18F marked affinity compound can be clinically applied and popularized as the tumor PET photographic developer targeted to the HER2 receptor.

The invention provides a classification and treatment system for breast cancer using measurements of and ligands for estrogen receptor, androgen receptor, vitamin D receptor, and optionally HER2 receptor.

The invention belongs to the field of radiopharmaceuticals, and particularly relates to an 18-labeling affinity type compound and a preparation method and application thereof. On one hand, the absorbing value of a tumor to the 18-labeling affinity type compound is high, and the tumor development sensitivity high; on the other hand, the absorbing value of the liver to the 18-labeling affinity type compound is low, and the toxic and side effect on the liver is little. Animal experiments show that the 18-labeling affinity type compound can serve as tumor PET photographic developer targeting an HER2 receiver due to the fact that the absorbing value of the tumor to the 18-labeling affinity type compound is high, the residence time is short, the target ratio / target-to-nontarget ratio is high, good pharmacokinetics characters are achieved, and the biological performance is excellent. The preparation method is low in cost, and easy, convenient and quick to operate, the labeling rate is high, the radiochemical purity of a labeled product is high, and the prepared 18-labeling affinity type compound serving as the tumor PET photographic developer tarting the HER2 receiver can be clinically applied and popularized easily.

The present invention provides a polypeptide compound with HER2 targeting function, which is composed of a HER2 affinity body and a bifunctional chelating agent connected through a polypeptide sequence; the polypeptide sequence is Met-Val-Lys; the polypeptide compound has a general structure The formula is shown in the following formula (I), wherein, R is a HER2 affinity body molecule, and X is a bifunctional chelating agent group. The present invention also provides a HER2-targeted radiolabeled complex using the polypeptide compound as a ligand. The radiolabeled complexes of the present invention can be used as radioactive diagnostic probes for the evaluation of HER2 receptors in breast cancer. The probes can reduce kidney accumulation while keeping tumor uptake unchanged, thereby improving tumor target and HER2 receptors. Non-target ratio, while reducing the radiation dose to the kidney. The present invention also provides the preparation method of the polypeptide compound and radiolabeled complex, and its application in the preparation of HER2-positive breast cancer radiodiagnostic and therapeutic probes for humans or animals.

The invention relates to application of an EGFR / HER2 inhibitor combined with a pyrimidine antimetabolic drug, in particular to application of an EGFR / HER2 receptor tyrosine kinase inhibitor combined with a pyrimidine antimetabolic drug in preparation of drugs for treating cancers.